Health-care companies rose as traders rotated back into the riskiest areas of the market, such as biotech and marijuana companies, emboldened by signs of a thaw in the U.S.-Chinese trade dispute.
DelMar Pharmaceuticals rallied after a cancer drug showed promise in a mid-stage clinical trial.
Regeneron shares rose as the Food and Drug Administration approved a new usage of one of the pharmaceutical company's eye treatments. Reports that an Ebola treatment was showing promise in clinical trials in the Democratic Republic of Congo was unlikely to affect Wall Street targets for earnings as the financial implications for Regeneron were unclear, analysts said.
Write to Rob Curran at email@example.com
(END) Dow Jones Newswires
August 13, 2019 16:54 ET (20:54 GMT)Copyright (c) 2019 Dow Jones & Company, Inc.